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SUMMARYEpendymal tumors across age groups are currently classified and graded solely by histopathology. It is,
however, commonly accepted that this classification scheme has limited clinical utility based on its lack of
reproducibility in predicting patients’ outcome. We aimed at establishing a uniform molecular classification
using DNA methylation profiling. Nine molecular subgroups were identified in a large cohort of 500 tumors,
3 in each anatomical compartment of the CNS, spine, posterior fossa, supratentorial. Two supratentorial
subgroups are characterized by prototypic fusion genes involving RELA and YAP1, respectively. Regarding
clinical associations, the molecular classification proposed herein outperforms the current histopathological
classification and thus might serve as a basis for the next World Health Organization classification of CNS
tumors.INTRODUCTION
Ependymal tumors are neuroepithelial malignancies of the CNS
that occur in both children and adults (Korshunov et al., 2010).
These tumors can arise along the entire neuroaxis comprising
the hemispheres, the hindbrain, and the spinal cord (Louis
et al., 2007). In children, 90% of ependymomas (EPNs) occur
intracranially, with two-thirds being located in the posterior
fossa (PF) and one-third within the supratentorial (ST) compart-
ment (Kilday et al., 2009). Across all age groups, more than 20%
of primary spinal cord tumors are of ependymal lineage (Ostrom
et al., 2014). The clinical behavior of ependymal tumors is highly
variable, and approximately 40% of patients are incurable
because of the paucity of effective treatment options available
(Gajjar et al., 2014; Korshunov et al., 2010; Merchant et al.,
2009; Ostrom et al., 2014). The 10-year overall survival (OS) is
about 64% in pediatric patients and ranges from 70% to 89%
in adult patients (Ostrom et al., 2014). Tumors in infancy are
associated with a particularly poor survival rate of only 42%–
55% at 5 years after diagnosis (Gatta et al., 2014). The extent
of surgical resection has for a very long time been the only clin-
ical prognostic marker in EPN known to be associated with
survival (Merchant et al., 2009). The current standard of care
includes maximal safe surgical resection, followed by focal
radiotherapy (Merchant et al., 2009). Nevertheless, a number
of reports indicate that a subset of patients with radically re-
sected ST tumors will not recur even without adjuvant therapy
(Venkatramani et al., 2012), exemplifying the need for better
patient stratification. Furthermore, although adjuvant chemo-
therapy is still part of many trial protocols, especially in young
children in an attempt to avoid or delay radiation therapy, mul-
tiple clinical trials have failed to show a survival benefit from
adding chemotherapy either at the time of primary diagnosisSignificance
DNAmethylation patterns in tumors have been shown to repre
origin throughout disease course, making them particularly sui
of a large series of ependymal tumors, comprising all histologic
classification for this clinically heterogeneous group of maligna
children), for whom effective therapeutic concepts are despera
subgroups identified, pointing to the clinical relevance ofmolec
minute amounts of DNA extracted from archived material, it isor at recurrence (Bouffet and Foreman, 1999; Bouffet et al.,
2009).
Accurate histopathological diagnosis according to the World
Health Organization (WHO) classification for CNS tumors (Louis
et al., 2007) is challenging for ependymal tumors. In particular,
distinction between grade II EPNs and grade III anaplastic
EPNs is often difficult, with poor interobserver reproducibility,
even if performed by the most experienced neuropathologists
(Ellison et al., 2011; Tihan et al., 2008). Grade I EPNs, i.e., myx-
opapillary EPNs (MPEs) (occurring in the spine) and subepen-
dymomas (SEs) (occurring across all compartments), generally
have more readily distinguishable histopathological character-
istics. However, complicating the grading of EPNs is the fact
that many tumors show isolated areas each representing
distinct grades, resulting in the challenge of predicting which
component of the tumor will influence the overall biologic
behavior.
Despite histopathological similarities among variants of EPN
at different anatomical sites, its molecular biology is heteroge-
neous, with distinct genetic and epigenetic alterations as well
as diverse transcriptional programs (Carter et al., 2002; Dyer
et al., 2002; Korshunov et al., 2010; Mack et al., 2014; Mendrzyk
et al., 2006; Parker et al., 2014; Wani et al., 2012; Witt et al.,
2011). Functional cross-species studies provide evidence that
these molecular differences reflect regionally discrete cells of
origin (Johnson et al., 2010; Parker et al., 2014; Taylor et al.,
2005). An association between neurofibromatosis type 2 (i.e.,
hereditary germline mutations of the NF2 gene), as well as spo-
radic mutations in NF2, has long been known as a hallmark ge-
netic aberration of spinal EPN (Ebert et al., 1999; Rubio et al.,
1994). Other single markers, including immunohistochemistry-
basedmarkers, have thus far failed to adequately reflect this bio-
logical heterogeneity and cannot reliably distinguish betweensent a very stable molecular memory of the respective cell of
table for tumor classification purposes. Methylation profiling
al grades and anatomical locations, revealed a highly reliable
ncies. Notably, the vast majority of high-risk patients (mostly
tely needed, were restricted to just two of the ninemolecular
ular classification. Since this analysis can be performed from
ideally suited for routine clinical application.
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histological grades and subgroups of EPNs. The single molecu-
lar marker that has repeatedly shown an association with unfa-
vorable outcome is gain of chromosome arm 1q (Godfraind
et al., 2012; Kilday et al., 2012; Korshunov et al., 2010; Mendrzyk
et al., 2006;Modena et al., 2012), particularly in PF EPNs of child-
hood. Homozygous deletion of the CDKN2A/B locus is associ-
ated with inferior prognosis, mainly in ST tumors (Korshunov
et al., 2010).
Only recently, large-scale genomic and epigenomic studies
have revealed the first driver genes in ST EPNs. Fusions between
RELA, which encodes an NF-kB component, and the poorly-
characterized gene C11orf95 caused by a local chromosome
shattering event (chromothripsis) on chromosome 11 were
seen in >70% of ST EPNs (Parker et al., 2014). Strikingly, this
fusion alone is sufficient to drive tumorigenesis when aberrantly
expressed in neural stem cells (Parker et al., 2014). For PF EPNs,
two distinct molecular subgroups were consistently identified in
two independent studies using different methods and non-over-
lapping patient cohorts (Wani et al., 2012; Witt et al., 2011).
These subgroups (provisionally termed PF Group A and Group
B, or PFA and PFB) are associated with distinct transcriptomic,
genetic, epigenetic, and clinical features and as such are much
more informative thanWHO grading alone (Archer and Pomeroy,
2011).
The current study aimed to establish a uniformmolecular clas-
sification of all ependymal tumors that adequately reflects the full
biological, clinical, and histopathological heterogeneity across
the major anatomical compartments, age groups, and grades.
RESULTS
DNA Methylation Profiling of Ependymal Tumors
Identifies Nine Distinct Molecular Subgroups
There is a growing body of evidence that DNA methylation
patterns of tumor cells, specifically of promotor regions, repre-
sent a very stable molecular memory of the respective cell of
origin throughout the disease course (Hoadley et al., 2014; Hov-
estadt et al., 2014), thus making this assessment particularly
suitable for tumor classification. To attempt such a classification
for ependymal tumors across all age groups and anatomical
compartments, we generated genome-wide DNA methylation
profiles for 500 ependymal tumors using the Illumina 450k
methylation array. Clinical parameters of the entire cohort are
presented in Figure S1 and Table 1.
Unsupervised hierarchical clustering of the DNA methylation
data using 10,000 probes with highest SD across the entire data-
set identified nine distinct subgroups of ependymal tumors,
three within each major compartment of the CNS: spine (SP),
PF, or ST (Figure 1A). Cluster analyses using different numbers
of probes (5,000, 20,000, or 50,000) gave the same results
(data not shown). Subgroup stability was further confirmed by
bootstrap analysis (bootstrap probability 0.999; p = 0.001).
Based on associations with anatomical location, histology, and
genetic alterations, as outlined below, we annotated these nine
subgroups as SP-SE (n = 7 samples), SP-MPE (n = 26), SP-
EPN (n = 21), PF-SE (n = 33), PF-EPN-A (n = 240), PF-EPN-B
(n = 51), ST-SE (n = 21), ST-EPN-YAP1 (n = 13), and ST-EPN-
RELA (n = 88). One of the subgroups within each compartment
was enriched with grade I SEs, and we therefore labeled them730 Cancer Cell 27, 728–743, May 11, 2015 ª2015 Elsevier Inc.as SP-SE, PF-SE, and ST-SE. Interestingly, some grade II
EPNs, confirmed after pathology re-review, also clustered with
these SE subgroups (Figures 1A and S2A). We then turned our
attention to the non-SE-like subgroups (a total of six) within
each of the three major anatomical compartments. Within the
spinal compartment, SP-MPE and SP-EPN showed a relatively
good concordance with the histopathological subtypes MPE
(grade I) and EPN (grade II) (Figure 1A). However, for the two re-
maining PF and ST subgroups, we found no concordance with
histological grading. Within the PF, the two non-SE-like sub-
groups represented previously described Group A and Group
B EPNs of the PF (Mack et al., 2014; Wani et al., 2012; Witt
et al., 2011), which for standardization purposes we termed
PF-EPN-A and PF-EPN-B. In the ST compartment, we sus-
pected that the largest subgroup probably represented EPNs
with recurrent C11orf95-RELA fusions, as described by Parker
et al. (2014). Indeed, when we performed RNA sequencing
and/or targeted analysis for the two major types of C11orf95-
RELA fusion transcripts (Figure S2B; Table S1), we found these
in 22 of 25 (88%) ST-EPN-RELA EPNs tested for RELA fusion
types 1 and 2, suggesting that the majority of cases in this sub-
group harbor these specific types of fusions. Interestingly, in one
case of the ST-EPN-RELA subgroup, negative for RELA fusion
types 1 and 2, we detected a PTEN-TAS2R1 fusion leading to
a frame shift and subsequent disruption of PTEN (Table S1).
Loss of PTEN expression/activity has previously been demon-
strated to induce NF-kB activity through activation of Akt/
mTOR (Dan et al., 2008), suggesting that alternativemechanisms
may exist that lead to activation of this key pathway in the ST-
EPN-RELA subgroup. We did not systematically test for other
less frequent fusions involving RELA as described by Parker
et al. (2014) (RELA fusion types 3-7), which likely account for
the majority of RELA fusion type 1 and 2 negative cases within
the ST-EPN-RELA subgroup.
Molecular Subgroups Remain Stable at Relapse
To evaluate further whether molecular subgroup classification
remains stable at disease recurrence, we performed hierarchi-
cal clustering of DNA methylation profiles of 45 primary epen-
dymal tumors and their corresponding recurrent tumor speci-
mens. In addition to primary tumors representing SP-MPE,
PF-SE, PF-EPN-A, PF-EPN-B, or ST-EPN-RELA subgroups,
the cohort comprised of 48 tumors from the time of first or sec-
ond recurrence. Notably, inspection of cluster groups relative
to patient identification number (1–45) showed that all recurrent
ependymal tumors clustered without exception directly next to
their corresponding primaries or very close to them, in all cases
within the same subgroup that was attributed to the primary tu-
mor (Figure 1B). These results strongly suggest that DNA
methylation profiling remains a reliable tool for subgroup iden-
tification not only at initial diagnosis, but also at the time of
recurrence.
YAP1 Gene Fusions Define a Distinct Subgroup
of ST EPNs
As RELA fusions were identified exclusively in the ST-RELA-
EPN subgroup, we next asked which genetic alterations might
underlie the other ST EPN subgroup in children, especially as
we identified several cases in this subgroup (9 of 13) with
Table 1. Overall Comparison of Clinical Data Associated with the Nine Molecular Subgroups of Ependymal Tumors
Molecular Subgroup
SP- PF- ST-
SE MPE EPN SE EPN-PFA EPN-PFB SE EPN-YAP EPN-RELA
Number of patients 7 26 21 33 240 51 21 13 88
Age (Years)
Range 22–68 9–66 11–59 39–76 0–51 10–65 25–70 0–51 0–69
Median 49 32 41 59 3 30 40 1.4 8
>18 7 100% 19 95% 20 95% 29 100% 2 1% 38 81% 13 100% 1 8% 20 24%
48 0 0% 1 5% 1 5% 0 0% 93 41% 9 19% 0 0% 4 30% 44 52%
<4 0 0% 0 0% 0 0% 0 0% 131 58% 0 0% 0 0% 8 62% 20 24%
NA 0 6 0 4 14 4 8 0 4
Gender
Male 3 43% 14 54% 12 63% 25 76% 154 65% 21 41% 15 71% 3 25% 57 65%
Female 4 57% 12 46% 7 37% 8 24% 84 35% 30 59% 6 29% 9 75% 31 35%
NA 0 0 2 0 2 0 0 1 0
Ratio (male:female) 1:1 1:1 1.7:1 3:1 1.8:1 0.7:1 2.5:1 0.3:1 1.8:1
Localization
PF 0 0% 0 0% 0 0% 29 100% 231 99% 49 98% 0 0% 1 8% 4 5%
ST 0 0% 1 6% 1 5% 0 0% 2 1% 1 2% 12 100% 12 92% 82 95%
SP 7 100% 17 94% 19 95% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%
NA 0 8 1 4 7 1 9 0 2
Histologic Grade
I 5 71% 20 83% 2 10% 21 66% 0 0% 0 0% 14 67% 0 0% 0 0%
II 2 29% 4 17% 17 85% 10 31% 69 30% 29 59% 7 33% 5 42% 20 23%
III 0 0% 0 0% 1 5% 1 3% 160 70% 20 41% 0 0% 7 58% 66 77%
NA 0 2 1 1 11 2 0 1 2
Level of Resection
Complete 3 60% 1 100% 5 71% 5 71% 116 53% 22 50% 3 60% 8 73% 41 65%
Incomplete 2 40% 0 0% 2 29% 2 29% 102 47% 22 50% 2 40% 3 27% 22 35%
NA 2 25 14 26 22 7 16 2 25
Radiotherapy
Yes 0 0% 0 0% 0 0% 2 14% 158 73% 40 85% 1 11% 5 50% 54 74%
No 0 0% 2 100% 8 100% 12 86% 59 27% 7 15% 8 89% 5 50% 19 26%
NA 7 24 13 19 23 4 12 3 15
Chemotherapy
Yes 0 0% 0 0% 0 0% 0 0% 163 75% 3 6% 0 0% 7 70% 26 36%
No 0 0% 1 100% 8 100% 7 100% 54 25% 44 94% 6 100% 3 30% 46 64%
NA 7 25 13 26 23 4 15 3 16
Progression
Yes 0 0% 1 50% 2 22% 3 33% 135 61% 14 30% 0 0% 2 20% 45 57%
No 5 100% 1 50% 7 78% 6 67% 87 39% 33 70% 6 100% 8 80% 34 43%
NA 2 24 12 24 18 4 15 3 9
Death
Yes 0 0% 0 0% 0 0% 0 0% 60 27% 2 4% 0 0% 0 0% 19 25%
No 5 100% 1 100% 9 100% 7 100% 159 73% 44 96% 6 100% 10 100% 57 75%
NA 2 25 12 26 21 5 15 3 12
Survival probability (%)
5-year PFS 100 50 88 83 33 73 100 66 29
5-year OS 100 100 100 100 68 100 100 100 75
10-year PFS 100 NA NA NA 24 56 100 NA 19
10-year OS 100 NA NA NA 56 88 100 NA 49
See also Figure S1.
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copy number aberrations on chromosome 11 around the YAP1
locus (Figure 2A). Parker et al. (2014) had already identified
YAP1 fusions in two ST EPN samples that were negative for
a RELA fusion. Therefore, it was tempting to speculate that
these cases might represent a separate molecular subgroup
of ST EPN. To test this hypothesis, we performed RNA
sequencing for 7 of the 13 cases that clustered with this sub-
group and for which sufficient high-quality RNA was available.
Consistent with our findings on the DNA copy-number level, we
detected the previously identified YAP1-MAMLD1 fusion
(Parker et al., 2014) in six of seven tumors and another gene
fusion containing YAP1 and an uncharacterized gene,
FAM118B, in the remaining tumor (Figures 2B and 2C). All
YAP1 fusions identified by RNA sequencing could be verified
by Sanger sequencing (Figure 2B). In the YAP1-MAMLD1 fu-
sions, exons 1–5 or 1–6 (out of 9) of YAP1 (according to refer-
ence sequence GenBank: NM_001130145) are fused in frame
to exons 2–7 or 3–7 of MAMLD1 (according to reference
sequence GenBank: NM_005491). In the other fusion, YAP1
exons 1–7 are fused in frame to the entire coding region en-
coded by exon 3–9 of FAM118B (according to reference
sequence GenBank: NM_024556). In both fusion proteins,
most of the N-terminal domains of the YAP1 protein are re-
tained, and for MAMLD1, most of the C-terminal part is re-
tained (Figure 2C). Importantly, no single YAP1 fusion was iden-
tified by RNA sequencing in any of 48 additional ependymal
tumors of the other molecular subgroups of the PF or ST re-
gion. This demonstrates that YAP1 fusion-positive cases char-
acterize another molecular subgroup of ST EPNs, annotated as
ST-EPN-YAP1, that are distinct from RELA fusion-positive ST
EPNs.
Molecular Subgroups Show Distinct Copy Number
Profiles
Genome-wide DNA copy number profiles, generated by using
the combined intensity values of the methylation probes (Hoves-
tadt et al., 2013), showed strong differences in numbers and
patterns of DNA copy number alterations (CNAs) between the
molecular subgroups (Figure 3). Strikingly, gene amplifications,
frequently seen in other brain tumors like medulloblastoma
and glioblastoma, were almost totally absent in ependymal tu-
mors. The same is true for homozygous gene deletions with
the exception of CDKN2A deletions, which were commonly
found in the ST-EPN-RELA subgroup (14 of 88; 16%), but not
in other subgroups (p < 0.001). This subgroup also shows
frequent loss of the entire chromosome 9 or chromosomal arm
9p (46 of 88; 52%), which is not seen in any other subgroup
(p < 0.001). Most CNAs across all subgroups involved gains or
losses of whole chromosomes indicating aneuploidy. Gains
and losses of chromosomal arms were much less frequent.Figure 1. Methylation Profiling Identifies the Existence of Nine Distinc
(A) Heat-map representation of an unsupervised clustering of DNA methylation p
represents a sample. The level of DNAmethylation (beta value) is represented with
location, histopathological diagnosis, and patient age are indicated.
(B) Heat map of methylation levels in primary ependymal tumors and correspon
ological diagnosis, and tumor type are indicated. Equal numbers at top of dend
individual.
See also Figure S2 and Table S1.Interestingly, ST-EPN-RELA tumors, but not tumors from the
other eight subgroups, frequently displayed dramatic copy-
number changes, reminiscent of chromothripsis (38 of 88;
43%), i.e., rearrangements of entire chromosomes or chromo-
somal arms with alternating copy number states (Korbel and
Campbell, 2013; Parker et al., 2014; Rausch et al., 2012). Chro-
mosome 11, where the C11orf95 and RELA genes are located,
was always involved in these events, but sometimes other chro-
mosomes were affected as well, yet to a much lesser extent (Fig-
ures 3 and S3; Table S2). Since Parker et al. (2014) extensively
demonstrated based on whole-genome sequencing data that
C11orf95-RELA fusions resulted from chromothripsis of chro-
mosome 11q, we inferred that the observed massive fragmenta-
tions of chromosome 11q in ST-EPN-RELA tumors are based on
this phenomenon. No chromothripsis was detected in tumors
classified as ST-EPN-YAP1, even though YAP1 is also located
on chromosome 11. Instead, these cases frequently displayed
focal CNAs around the YAP1 locus (Figure 2A). Surprisingly, be-
sides the CNAs on chromosome 11, the remainder of the
genome is relatively stable in most ST-EPN-YAP1 tumors, which
is in contrast to the ST-EPN-RELA EPNs that typically show an
abundance of CNAs. Predominantly stable genomes were also
seen in SEs of all three anatomical compartments (SP-SE, PF-
SE, ST-SE). As expected, this was also true for the PF-EPN-A
subgroup. The only CNA that was frequently observed in both
SP-SE and PF-SE, but not ST-SE, was a complete or partial
loss of chromosome 6, in line with previous findings (Kurian
et al., 2008). Loss of chromosome 6 is also frequently seen in
PF-EPN-B tumors, where it is the most frequent CNA (42 of 51
tumors, 82%), and to a lesser extent in SP-EPN, PF-EPN-A,
and ST-EPN-RELA tumors. For PF-EPN-A tumors, the most
frequent CNA observed was gain of 1q (60 of 240; 25%), which
was also seen in PF-EPN-B (9 of 51; 18%), and ST-EPN-RELA
tumors (21 of 88; 24%). Many more CNAs are seen in both
SP-MPE and SP-EPN, with the most frequent event being loss
of 22q in SP-EPN tumors (19 of 21; 90% show loss of 22q).
This frequent involvement of the 22q locus is not surprising as
it includes NF2, which is known to be frequently mutated in spi-
nal EPNs (Ebert et al., 1999; Slavc et al., 1995). However, loss of
22q is not entirely restricted to SP-EPN, as it is also seen at
lower frequencies in other subgroups (Figure 3). It remains to
be seen whether NF2 also plays a role in these subgroups or
whether other genes on 22q are involved. Finally, aside from
ST-EPN-RELA tumors displaying chromothripsis, tumors in the
PF-EPN-B subgroup show by far the highest degree of genomic
instability, with many gains and losses of entire chromosomes or
(less frequent) chromosomal arms in each tumor (Figure 3). Alto-
gether, these data show that ependymal tumors of the nine mo-
lecular subgroups indeed represent genetically highly distinct
entities.t Epigenetic Subgroups of Ependymal Tumors
rofiles of 500 ependymal tumors. Each row represents a probe; each column
a color scale as depicted. For each sample, subgroup association, anatomical
ding recurrent diseases. Molecular subgroup, anatomical location, histopath-
rogram and arrows at the bottom indicate that samples derive from the same
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Figure 3. Molecular Subgroups of Ependymal Tumors Show Distinct Copy-Number Profiles
Overview of chromosomal aberrations in the nine molecular subgroups of ependymal tumors. DNA methylation array-based copy-number variation plots were
scored for loss (red), gain (green), no change (= balanced; gray), or chromothripsis (purple) for all chromosomal arms. Additional focal aberrations were scored for
chromosome 11q only (blue). Results were plotted as frequencies at which these aberrations occurred within each molecular subgroup; p values on the right
indicate whether there was a significant difference in the distribution of these frequencies across the nine subgroups (chi-square test).
See also Figure S3 and Table S2.Transcription Profiles Reveal Distinct Druggable
Pathways in Molecular Subgroups
To investigate whether (epi)genetically defined molecular sub-
groups of ependymal tumors also show subgroup-specific
transcriptional differences, we generated gene expression pro-Figure 2. Recurrent YAP1 Fusion Transcripts in a Distinct ST Subgrou
(A) Copy-number variation plots of four ST tumors classified as ST-EPN-YAP1
highlighting existence of global and/or focal aberrations. Sample identifications
(B) Electropherograms of the fusion transcripts detected in the tumor samples dep
upstream and downstream fusion sites.
(C) Predicted YAP1 fusion products at protein level. Red dashed lines indicate fus
bottom.files for all tumor samples, for which sufficient high-quality
RNA was available. This resulted in 209 gene expression pro-
files generated on the Affymetrix U133 Plus2.0 array. Unfortu-
nately, ependymal tumors of the SP-SE subgroup were not
included because no RNAs were available. Unsupervisedp
based on DNA methylation. Red rectangular marks chromosomal arm 11q
are indicated.
icted in (A). Numbers flanking the indicated breakpoint (dashed line) represent
ion sites. Proteins are drawn to scale, and protein domains are indicated at the
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hierarchical cluster analysis of the gene expression data
almost perfectly recapitulated the molecular subgroups
derived by DNA methylation profiling (Figure S4). To identify
genes that are specifically (over)expressed in only one of the
subgroups, we performed supervised analyses by comparing
gene expression patterns of each subgroup against all other
subgroups. This resulted in the identification of multiple genes
that are either exclusively expressed or at least highly overex-
pressed specifically in one of the subgroups. A heat map
showing the expression of these signature genes across all
molecular subgroups is displayed in Figure 4A. In addition,
gene expression patterns of two representative genes per
subgroup are displayed (Figure 4B). The full list of signature
genes (Table S3) provides a first hint of the underlying biology,
pathway activation, and potential drug targets in the distinct
molecular subgroups. For instance, KIT, targetable by several
multikinase inhibitors, is only expressed at high levels in PF-SE
tumors and not in other subgroups (Figure 4B). Another
example is RELA, the transcription factor involved in activating
the NF-kB pathway, which is only expressed in ST-EPN-RELA
tumors (Parker et al., 2014). In order to get an even better
insight in the biological processes and pathways that play a
role in each of these subgroups, we performed gene-ranked
pathway enrichment analysis with g:Profiler (Reimand et al.,
2011) and used Cytoscape Enrichment Map to visualize pro-
cesses and pathways that distinguished the different molecu-
lar subgroups or anatomical compartments (Figure 4C). Gene
sets were compiled from the Gene Ontology (GO) biological
processes, as well as Kyoto Encyclopedia of Genes and Ge-
nomes (KEGG), Reactome, and CORUM databases of path-
ways and protein complexes. Significant gene sets (false dis-
covery rate [FDR] < 0.05, p < 0.01) (Table S3) were visualized
as interaction networks (Figure 4C). Interestingly, while several
gene sets involved in brain development clearly play a role in
all subgroups, as expected, other gene sets were specific to
certain subgroups. For instance, cell cycle genes, cell migra-
tion genes or genes involved in MAPK signaling were most
active in PF-EPN-A tumors and ST-EPN-RELA tumors, while
cAMP/carbohydrate metabolism or dopamine signaling genes
were more active in ST-EPN-YAP1 tumors. Ciliogenesis genes
were exclusively found in PF-EPN-B tumors. The clear differ-
ences in active biological processes and pathways identified
between the various molecular subgroups of ependymal tu-
mors, in line with previous data for the PF subgroups (Witt
et al., 2011), further support their distinct origins and may sug-
gest possible avenues for future subgroup-specific targeted
therapies.Figure 4. Transcription Profiles of Ependymal Tumors Reveal Subgrou
(A) Heat-map representation of signature genes across the molecular subgroups
Subgroup affiliation of samples (column) and signatures (row) is indicated by colo
(B) Relative expression levels of two representative signature genes per subgro
represent the interquartile range (IQR), with the median represented by a solid lin
(C) Pathway enrichment analysis comparing each of themolecular subgroups SP-
EPN-B (blue), ST-SE (dark violet), ST-EPN-YAP1 (cyan), and ST-EPN-RELA (red
Distinct pathways and biological processes between the molecular subgroups o
enriched gene sets, which are grouped and annotated by their similarity accordin
within each gene set. The illustrated network map was simplified by manual cura
not included due to lack of RNA.
See also Figure S4 and Table S3.Molecular Subgroups Correlate with
Clinicopathological Variables
The nine molecular subgroups of ependymal tumors described
herein were closely associated with specific age groups (Figures
1 and S1; Table 1). All three SE-like subgroups were exclusively
found in adults (18 years and older, range 22–76), with median
ages of 49 years (SP-SE), 59 years (PF-SE), and 40 years (ST-
SE), respectively. The other two SP subgroups, SP-MPE and
SP-EPN, were also mainly found in adults, but some occurred
in children (SP-MPE median age 32 years, range 9–66; SP-
EPN median age 41 years, range 11–59). Patients in the PF-
EPN-B subgroupwere foundmostly in the adolescent and young
adult populations (median age 30 years, range 10–65). In
contrast, tumors in the other PF subgroup, PF-EPN-A, were
almost exclusively found in young children (median age 3 years,
range 0–51). Only two patients in this subgroup were older than
18. The remaining two ST subgroups, ST-EPN-YAP1 and ST-
EPN-RELA, were much more common in children (ST-EPN-
YAP1 median age 1.4 years, range 0–51; ST-EPN-RELA median
age 8 years, range 0–69), but a significant portion (23%) of
the ST-EPN-RELA tumors was also found in adults. Gender dis-
tribution in our cohort revealed a preponderance of males over
females (1.6:1). The gender distribution of all subtypes is pre-
sented in Table 1, with some significant differences between
subgroups (p = 0.004). For example, among PF tumors, there
was a preponderance of males represented in the PF-EPN-A
(male:female = 1.8:1) and PF-SE (male:female = 3:1) subgroups,
whereas in the PF-EPN-B subgroup, males were in the minority
(male:female = 0.7:1).
Risk Stratification byMolecular Subgrouping Is Superior
to Histopathological Grading
Survival analyses for all patients with available outcome data (n =
388) showed remarkable differences in OS and progression-free
survival (PFS) between the molecular subgroups (Figure 5). Both
the PF-EPN-A and ST-EPN-RELA subgroups show a dismal
outcome, with 10-year OS rates of 50% and PFS rates of
20%. Notably, patients comprising these subgroups are
mostly pediatric. All other subgroups have a much better
outcome, with 5-year OS rates around 100% and 10-year OS
rates ranging from 88%–100% (Table 1). It is well known that pa-
tients with ependymal tumors within the spinal region can usually
be cured by complete neurosurgical resection alone. In our
study, the number of spinal tumors was not sufficient to derive
clinically meaningful conclusions, but the favorable OS rates
(OS 100% for all three subgroups) are consistent with published
literature (McGuire et al., 2009) (Figure S5). As one example forp-Specific Gene Signatures and Pathways
of ependymal tumors generated from supervised gene expression analyses.
r codes. SP-SE subgroup cases were not included due to unavailability of RNA.
up as compared with the other subgroups are shown as box plots. Box plots
e.
MPE (dark green), SP-EPN (yellow), PF-SE (deep pink), PF-EPN-A (orange), PF-
) against all other subgroups and a collection of normal brain control samples.
f ependymal tumors are illustrated (FDR corrected p < 0.01). Nodes represent
g to related gene sets. Node size is proportional to the total number of genes
tion to remove general and uninformative sub-networks. SP-SE samples were
Cancer Cell 27, 728–743, May 11, 2015 ª2015 Elsevier Inc. 737
A B
C D
Figure 5. Molecular Subgroups of Ependymal Tumors Correlate with Distinct Clinical Outcome
(A–D) Kaplan-Meier curves for overall (A and C) and progression-free (B and D) survival for infratentorial (A and B) and ST (C and D) molecular ependymal tumor
subgroups defined by methylation profiling. The p values were computed by log rank tests between subgroups. Numbers of patients at risk are indicated.
See also Figure S5.the clinical utility of molecular subgrouping over conventional
histopathology, the SE-like molecular subgroups from the PF
and ST compartments all showed favorable outcomes on OS
analysis. Since a substantial proportion of molecular SEs was
classified as grade II and even grade III EPN (Figures 1A and
S2; Table 1), molecular classification in these instances reveals
tumor subgroups with favorable outcome that would not be
yielded by histopathological analysis. Notably, albeit OS rates
are excellent for PF-SE and ST-SE, only SE tumors from the
PF show frequent progression (Figure 5). This clinical course is
reminiscent of PF-EPN-B tumors, which cluster close to the
PF-SE subgroup, suggesting also some biological similarities738 Cancer Cell 27, 728–743, May 11, 2015 ª2015 Elsevier Inc.between these two subgroups. Examining other clinical vari-
ables, for either compartment-specific or subgroup-specific
prognostic value, showed that extent of resection was associ-
ated with OS in PF-EPN-A (p = 0.01) and with PFS in both PF-
EPN-A (p = 0.0004) and PF-EPN-B (p = 0.019) (Figure S6A).
Other clinical variables that showed prognostic value in univari-
ate analyses across all subgroups included age (outcome of chil-
dren is worse than adults) and chemotherapy (patients who
received chemotherapy did worse than patients who did not
receive chemotherapy; Table S4). However, both these factors
were strongly biased by the molecular subgrouping as the two
subgroups that showed the worst outcome, PF-EPN-A and
Table 2. Multivariate Cox Proportional Hazard Models for Overall and PFS of Molecular Subgroups of Ependymal Tumors
Variable Hazard Ratioa 95% CI p Valueb
OS
1q gain (yes versus no) 2.44 1.49–4 <0.0001
WHO III versus WHO II 1.06 0.61–1.82 0.827
Age, years (<4 versus >18) 0.46 0.14–1.53 0.21
Age, years (4–18 versus >18) 0.63 0.20–1.95 0.429
Resection (STR versus GTR) 1.79 1.11–2.90 0.017
Chemotherapy (yes versus no) 1.44 0.81–2.56 0.205
Radiotherapy (yes versus no) 0.81 0.43–1.52 0.528
PF-SE versus PF-EPN-B 1.45 0.06–33.87 0.814
PF-EPN-A versus PF-EPN-B 6.65 1.35–32.56 0.019
ST-SE versus PF-EPN-B 1.89 0.08–44.09 0.691
ST-EPN-YAP versus PF-EPN-B 1.97 0.08–46.31 0.673
ST-EPN-RELPOS versus PF-EPN-B 6.22 1.32–29.27 0.021
Likelihood Ratio Test
Full model versus model without methylation subgroups (OS) 0.03
Full model versus model without WHO (OS) 0.79
PFS
1q gain (yes versus no) 1.79 1.27–2.52 0.001
WHO III versus WHO II 0.89 0.63–1.27 0.547
Age, years (< 4 versus > 18) 1.18 0.55–2.53 0.665
Age, years (4-18 versus > 18) 1.39 0.68–2.83 0.364
Resection (STR versus GTR) 1.79 1.31–2.45 <0.0001
Chemotherapy (yes versus no) 0.93 0.64–1.34 0.715
Radiotherapy (yes versus no) 0.75 0.50–1.10 0.149
PF-SE versus PF-EPN-B 1.23 0.30–5.024 0.771
PF-EPN-A versus PF-EPN-B 2.50 1.13–5.56 0.024
ST-SE versus PF-EPN-B 0.29 0.01–5.27 0.407
ST-EPN-YAP versus PF-EPN-B 0.68 0.11–3.95 0.67
ST-EPN-RELPOS versus PF-EPN-B 2.66 1.21–5.86 0.015
Likelihood Ratio Test
Full model versus model without methylation subgroups (PFS) 0.01
Full model versus model without WHO (PFS) 0.56
See also Figure S6 and Table S4.
aWith Firth’s correction.
bWald test.ST-EPN-RELA, were also the subgroups that were mainly pedi-
atric and in which most patients received chemotherapy as
compared with the other subgroups. Within each of these sub-
groups, however, patients who received chemotherapy showed
no significant survival improvement compared with patients who
did not receive chemotherapy (data not shown). WHO grading
and radiotherapy had no prognostic value in these univariate an-
alyses, neither within anatomical compartments nor within mo-
lecular subgroups (Figure S6B; Table S4). In linewith previous re-
ports (Godfraind et al., 2012; Korshunov et al., 2010), gain of
chromosome 1q also showed strong prognostic value in the pre-
sent series. However, a highly significant difference in OS be-
tween tumors with and without gain of 1q was only seen for
the PF-EPN-A tumors (p = 0.00001; Figure S6C), while no signif-
icant differences in OS were seen for PF-EPN-B or ST-EPN-
RELA tumors, even though all three subgroups displayed similarfrequencies of 1q gain (PF-EPN-A: 25%; PF-EPN-B: 18%; ST-
EPN-RELA: 24%; Figure 3). Surprisingly, however, 1q gain
showed a strong prognostic association regarding PFS not
only in PF-EPN-A but also in PF-EPN-B tumors, but not in the
ST-EPN-RELA subgroup (PF-EPN-A: p = 0.0068; PF-EPN-B:
p = 0.0075; Figure S6C).
Finally, we performed amultivariate Cox regression analysis to
see whether molecular subgrouping, level of resection, and 1q
gain are independent prognostic parameters for ependymal tu-
mors. For comparison, we also included the clinical variables
WHO grade and radiotherapy, even though they showed no
prognostic value in the univariate analyses (Figure S6; Table
S4). Results presented in Table 2 show thatmolecular subgroup-
ing, level of resection, and 1q gain are all independent prognostic
parameters for both OS and PFS. Additional parameters
examined, including age and chemotherapy, did not haveCancer Cell 27, 728–743, May 11, 2015 ª2015 Elsevier Inc. 739
Figure 6. Graphical Summary of Key Molec-
ular and Clinical Characteristics of Ependy-
mal Tumor Subgroups
Schematic representation of key genetic and
epigenetic findings in the nine molecular sub-
groups of ependymal tumors as identified by
methylation profiling. CIN, Chromosomal insta-
bilityindependent prognostic value in multivariate analysis. In addi-
tion, a likelihood-ratio test was performed to compare the full
model including all variables with a multivariate Cox model that
does not include molecular subgrouping. The resulting p values
were p = 0.039 for OS and p = 0.012 for PFS, indicating that add-
ing molecular subgrouping significantly improved the model fit.
In contrast, comparing the full model with a model that omits
WHO grading led to non-significant p values for OS (p = 0.79)
and PFS (p = 0.56), indicating that WHO grading did not improve
the model when other variables were already included (Table 2).
DISCUSSION
Based on genome-wide DNAmethylation patterns, we identified
nine distinct molecular subgroups of ependymal tumors across
all age groups, three in each anatomical compartment of
the CNS (SP, PF, and ST). We have shown that these molecular
subgroups are genetically, epigenetically, transcriptionally,
demographically, and clinically distinct. Whether they also have
different cells of origin, as suggested by Johnson et al. (2010), re-
mains to be proven and requires further functional studies,
although it seems an attractive hypothesis. A robust and uniform
(epi)genetic classification of ependymal tumors as presented
herein may guide researchers, neuropathologists, and clinicians
to a better understanding of the heterogeneity of this disease,
analogous to (epi)genetic subgroups of medulloblastoma (Kool
et al., 2012; Northcott et al., 2012; Taylor et al., 2012) and glio-
blastoma (Brennan et al., 2013; Sturm et al., 2012, 2014). Since
methylation profiling can be reliably performed from very small
amounts of DNA extracted from formalin-fixed and paraffin-
embedded tissue (Hovestadt et al., 2013), this technique lends it-740 Cancer Cell 27, 728–743, May 11, 2015 ª2015 Elsevier Inc.self to routine clinical application. Herein,
we also show that molecular subgrouping
remains stable throughout the course of
disease, in line with previous findings for
medulloblastoma (Ramaswamy et al.,
2013) and anticipated from the fact that
DNA methylation profiles largely reflect
an epigenetic memory of the cell of origin.
Molecular subgrouping may also help
identifying more effective therapeutic
strategies, especially for the pediatric
ependymal subgroups PF-EPN-A and
ST-EPN-RELA that show a dismal
outcome with current treatment ap-
proaches. A graphical illustration of the
key genetic and clinical features of these
nine molecular subgroups of ependymal
tumors is given in Figure 6.The nine subgroupswe identified herein showed some overlap
with previously identified subgroups A to I of EPN using gene
expression profiling (Johnson et al., 2010). The ST subgroups C
and D in that study mainly represent our ST-EPN-RELA and ST-
SE subgroups, respectively. Spinal subgroup E represents our
SP-MPE subgroup, whereas the mixed spinal/PF subgroup F
represents our SP-EPN and PF-EPN-B subgroups, respectively.
SubgroupsG,H, and I allmainly represent PF-EPN-A tumorswith
some PF-SE tumors. No ST-EPN-YAP1 tumors are represented
in the study of Johnson et al. (2010), and subgroups A and B
mainly seem to contain non-EPNs. Our data, based on a much
larger cohort, are able to show that ST EPNs harboring a YAP1
fusion, as first identified by Parker et al. (2014), are molecularly
and clinically distinct from ST EPNs harboring a RELA fusion. In
fact, seven of seven (100%) of the ST-EPN-YAP1 cases tested
harbored a YAP1 fusion, with the most common fusion being
YAP1-MAMLD1 identified in six of seven (86%) and another
fusion (YAP1-FAM118B), identified in one of seven (14%) of the
cases. We did not find YAP1 fusions in tumors of any other sub-
group for which we had RNA sequencing data available. Both
YAP1-MAMLD1 and YAP1-FAM118B fusions have not been re-
ported before in any other type of tumor and the exact function
of these fusions remains to be investigated. However, it is
highly likely that these YAP1 fusions comprise the oncogenic
drivers in this distinct subgroup of ST EPN, also because a recent
report showed that high YAP1 activity is sufficient to induce
embryonal rhabdomyosarcoma (Tremblay et al., 2014). Interest-
ingly, a similar fusion between YAP1 and MAML2 has been
found in nasopharyngeal carcinomas (Valouev et al., 2014).
MAMLD1 and MAML2, both members of the Mastermind
gene family, are transcriptional co-activators of NOTCH
signaling and probably function in the respective fusion proteins
as NOTCH independent co-activators of TEAD-mediated HIPPO
signaling, leading to transformation and increased proliferation
(Wu et al., 2002). Whether FAM118B may have similar func-
tion is unknown, but a recent report showed that silencing
FAM118B expression in HELA cells resulted in decreased pro-
liferation (Li et al., 2014).
RELA type 1 and type 2 fusions (Parker et al., 2014) were
commonly found in ST-EPN-RELA tumors, but not in any
other subgroup, strongly suggesting that these C11orf95-RELA
fusions are the principal drivers of ST-EPN-RELA subgroup
tumors. Interestingly, while homozygous CDKN2A deletions
were frequently detected in ST-EPN-RELA tumors, they were
not found in ST-EPN-YAP1 tumors. Previous studies showed
that homozygous CDKN2A deletions are associated with a
dismal outcome (Korshunov et al., 2010; Witt et al., 2011), which
fits with the present results. Moreover, in ST-EPN-RELA tumors,
the recurrent RELA fusion appears to be a result of heavily rear-
ranged genomes, in many cases in conjunction with a chromo-
thripsis event affecting chromosome 11. In contrast, ST-EPN-
YAP1 tumors never showed evidence of chromothripsis and
had relatively stable genomes, with the only recurrent rearrange-
ments affecting the locus of YAP1. What exactly is causing chro-
mothripsis and why it is specific to ST-EPN-RELA tumors and
absent in the other subgroups is unknown and requires further
investigation. It is plausible that CDKN2A has a role in chromo-
thripsis, as it affects the TP53 pathway, which has been shown
to be involved in chromothripsis in other entities (Rausch et al.,
2012), but we found no direct correlation between chromothrip-
sis and focal CDKN2A deletions. In our cohort, TP53 was not
sequenced, but it is known that TP53 mutations are extremely
rare in EPN (Gaspar et al., 2006; Ohgaki et al., 1993).
The only other molecular subgroup for which a recurrent ge-
netic mutation is known is the SP-EPN subgroup (Figure 6). In
this group of ependymal tumors, occurring in the spinal column
and affecting predominantly adults, NF2 is frequently mutated
(Ebert et al., 1999; Slavc et al., 1995), and almost all tumors in
this subgroup (19 of 21; 90%) showed monozygosity of 22q.
Loss of 22q was also observed in several other intracranial
molecular subgroups, but in these subgroups, it is unlikely
that NF2 is the target, as NF2 is not frequently mutated in
intracranial ependymal tumors (Singh et al., 2002). In fact,
recent sequencing studies have not found a single recurrent
mutation in PF EPNs or any other recurrent mutation outside
the recurrent C11orf95-RELA gene fusions in ST EPNs (Mack
et al., 2014; Parker et al., 2014). It therefore remains to be seen
which oncogenic drivers exist in the other molecular subgroups
and what role CNAs and epigenetic alterations play.
An important observation from our data is that the two ST sub-
groups of EPN, characterized by highly recurrent but different
gene fusions, have a different clinical outcome, even though
they appear in the same age groups and in the same anatomical
compartment. While patients in the ST-EPN-RELA subgroup
comprise high-risk patients, with a 10-year OS of around 50%
and a 10-year PFS of around 20%, patients in the ST-EPN-
YAP1 subgroup all survived, and only one of six recurred. While
this observation is striking, definite conclusions regarding the
prognosis of ST-EPN-YAP1 tumors will have to await validation
in larger patient cohorts. Besides ST-EPN-RELA, the only othermolecular subgroup of ependymal tumors associated with a
poor outcome is the PF-EPN-A subgroup, in keeping with previ-
ously published data for this subgroup of PF EPNs (Mack et al.,
2014;Wani et al., 2012;Witt et al., 2011). Patients in all other sub-
groups have more favorable prognosis. As we have shown in
multivariate survival analyses, molecular subgrouping is superior
to histopathological grading of ependymal tumors, confirming
previous studies showing the inconsistent prognostic value of
histopathological grading (Ellison et al., 2011; Tihan et al.,
2008). In fact, the only other variables that endured as indepen-
dent prognostic factors in this multivariate analysis besides
molecular subgrouping were extent of surgical resection and
1q gain.
In spite of its known shortcomings, histopathological grading
based on WHO criteria has been used in several clinical trials
to stratify EPN patients into different treatment groups, namely
the Children’s Oncology Group study ACNS0121 and the
German HIT 2000 Ependymoma trial. We propose a uniform
and robust molecular classification system, based on nine
distinct subgroups, as superior alternative to the current
WHO histopathological classification. The logical next step will
be to validate and further refine our findings in large, prospec-
tively treated patient cohorts, such as cohorts of international
cooperative group trial studies. We expect that a refined molec-
ular risk stratification of patients will be of utmost value for
designing prospective clinical trials that tailor therapy to the pa-
tients’ risk profile. Furthermore, the efficacy of adjuvant thera-
pies, such as radiotherapy, chemotherapy, and/or molecular tar-
geted therapies will need to be assessed in the context
of specific molecular subgroups, as they will likely differ in their
response to different therapy modalities. Thus, we believe that
our proposed molecular classification of ependymal tumors will
not only improve current diagnostic accuracy and prognostica-
tion, but also provide a superior platform for future clinical trial
development, with the ultimate goal of improving the morbidity
and mortality of children and adults with EPN.
EXPERIMENTAL PROCEDURES
Tumor Material and Patient Characteristics
Clinical samples and data were collected after receiving written informed con-
sent according to protocols approved by the institutional review boards,
includingUniversityHospital Heidelberg, NNBurdenkoNeurosurgical Institute,
TheHospital forSickChildren,University ofUtah, SchneiderChildren’sMedical
Center of Israel, University of Colorado Denver, University Hospital Brno, Uni-
versity of California San Francisco, NYU LangoneMedical Center, University of
Cambridge, University of Bonn, andMDAndersonCancerCenter. At least 80%
of tumor cell content was estimated in all tumor samples by staining cryosec-
tions (5 mm thick) of the piece from which nucleic acid extraction was per-
formedwith H&E. Diagnoses were confirmed by histopathological assessment
by at least two independent neuropathologists, including a central pathology
review at the departments of neuropathology at theMDAnderson Cancer Cen-
ter, the University Hospital Heidelberg, or the University Hospital Bonn that uti-
lized the 2007 WHO classification for CNS tumors. The following tumor types
were included: SE (WHO grade I), MPE (WHO grade I), EPN (WHO grade II),
and anaplastic EPN (WHO grade III). No patient underwent chemotherapy or
radiotherapy prior to the surgical removal of the primary tumor. Detailed clinical
and patient characteristics are shown in Figure S1 and Table 1.
Biostatistics
Independence of chromosomal aberrations along molecular subgroups was
analyzed by chi-square tests, where p values have been computed byCancer Cell 27, 728–743, May 11, 2015 ª2015 Elsevier Inc. 741
100,000 Monte Carlo simulations. The distribution of gender within molecular
subgroups was tested against a null proportion of 0.5 using exact binomial test
based on Clopper-Pearson intervals. Distribution of survival times was esti-
mated by using Kaplan-Meier estimates and compared with the log-rank
test. Prognostic impact of covariates on PFS and OSwas evaluated on the ba-
sis of hazard ratios and 95% CIs from Cox’s proportional hazards regression
model. Multivariate Cox’s proportional hazards regression models were
used to adjust effects for additional covariates. In addition, Firth’s correction
was applied to account for the monotone likelihood problem arising due to to-
tal separation of group and events (Heinze and Schemper, 2001). To compare
nested Cox proportional hazards models Likelihood-ratio tests were applied.ACCESSION NUMBERS
The DNA methylation and gene expression data of this study have been
deposited in NCBI’s Gene Expression Omnibus (GEO; http://www.ncbi.nlm.
nih.gov/geo) and are accessible through GEO Series accession numbers
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